[Important: Before reading the following post, please see my ‘disclaimer
A friend who is retired from the pharmaceutical industry recently gave me a lead on a new drug for treating some forms of blood diseases.
Pharmacyclics has had positive data on the treatment of CLL . Their new drug is call Ibrutinib. It is now going through the FDA process and may be approved soon.
According to the company, Ibrutinib basically blocks signals from the B-cell receptor by inhibiting the function of the BTK enzyme and kills the B-cell cancer. To date, seven phase 3 studies have been initiated with ibrutinib. The product is still going through additional studies to evaluate its efficacy against other B-cell cancers, including myeloma and lymphoma.
Apparently Pharmacyclics has signed a deal with Janssen Biotech, a subsidiary of Johnson & Johnson for the development and commercialization of ibrutinib to treat CLL.
For more info on this go to these links: